April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Efficacy of Topical Azithromycin Ophthalmic Solution 1.0% in the Treatment of Contact Lens-Related Dry Eye
Author Affiliations & Notes
  • Katherine M. Bickle
    The Ohio State University College of Optometry, Columbus, Ohio
  • Kelly K. Nichols
    The Ohio State University College of Optometry, Columbus, Ohio
  • Reza Haque
    Inspire Pharmaceuticals, Durham, North Carolina
  • Rich C. Zink
    Inspire Pharmaceuticals, Durham, North Carolina
  • Mike Schiewe
    Inspire Pharmaceuticals, Durham, North Carolina
  • Jason J. Nichols
    The Ohio State University College of Optometry, Columbus, Ohio
  • Footnotes
    Commercial Relationships  Katherine M. Bickle, None; Kelly K. Nichols, Inspire, Pfizer, Allergan, Alcon (R), Inspire, Pfizer, Allergan, Alcon, Tearlab (C); Reza Haque, Inspire (E); Rich C. Zink, Inspire (E); Mike Schiewe, Inspire (E); Jason J. Nichols, Alcon, CIBA Vision, Vistakon (R), Inspire (F)
  • Footnotes
    Support  Inspire Pharmaceuticals, NIH T35EY07151
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3842. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katherine M. Bickle, Kelly K. Nichols, Reza Haque, Rich C. Zink, Mike Schiewe, Jason J. Nichols; Efficacy of Topical Azithromycin Ophthalmic Solution 1.0% in the Treatment of Contact Lens-Related Dry Eye. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3842.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of a 4-week treatment with azithromycin ophthalmic solution 1% for contact lens-related dry eye.

Methods: : This was a four-week, single-center, open-label clinical study in patients diagnosed with contact lens-related dry eye using the Contact Lens Dry Eye Questionnaire (CLDEQ). Fifty patients were randomized to one of two treatment groups: topical azithromycin solution administered BID on days 1 & 2 and QD on days 3-29 or Visine for Contacts rewetting drops administered QID on days 1-29. Patient diaries were utilized daily to collect data on comfortable and total contact lens wearing time and ocular dryness throughout the treatment period. Tear osmolarity was also assessed.

Results: : Fifty patients were enrolled and forty-four completed the study. One patient discontinued in the azithromycin group and five patients discontinued in the rewetting drops group due to adverse events. A significant increase from baseline was observed in the comfortable contact lens wear time for subjects treated with topical azithromycin as compared to subjects treated with rewetting drops at Week 4 (p = 0.004; primary endpoint). Statistical significance was also achieved at Weeks 1, 2 and 3. The improvement in comfortable wear time exceeded 2 hours throughout the treatment period (Weeks 1-4). No significant differences were observed between groups for total wear time or tear osmolarity. Subject-rated ocular dryness (PM time assessments) was significantly improved from baseline in the subjects treated with azithromycin as compared to rewetting drops (entire treatment period; p = 0.02). Additionally, a statistical difference was observed in favor of the azithromycin treatment group at Week 2 for a non-dry eye classification as determined by the CLDEQ (p = 0.05).

Conclusions: : Treatment with topical azithromycin ophthalmic solution 1% was well-tolerated and resulted in a significant improvement in comfortable contact lens wear time in patients with contact lens-related dry eye.

Clinical Trial: : http://www.clinicaltrials.gov NCT01105624

Keywords: cornea: tears/tear film/dry eye • contact lens • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×